Prostatype Genomics AB Asset Resilience Ratio
Prostatype Genomics AB asset resilience ratio. Prostatype Genomics AB (PROGEN) has an Asset Resilience Ratio of -10.72% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PROGEN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Prostatype Genomics AB (2021–2023)
Asset resilience ratio of Prostatype Genomics AB from 2021 to 2023. This chart shows how Prostatype Genomics AB's Asset Resilience Ratio has changed over time. Read total liabilities of Prostatype Genomics AB for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Prostatype Genomics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PROGEN total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-3.73 Million | -10.72% |
| Total Liquid Assets | Skr-3.73 Million | -10.72% |
Asset Resilience Insights
- Limited Liquidity: Prostatype Genomics AB maintains only -10.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Prostatype Genomics AB Industry Peers by Asset Resilience Ratio
Compare Prostatype Genomics AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Prostatype Genomics AB Asset Resilience Ratio by Year (2021–2023)
Prostatype Genomics AB asset resilience ratio by year from 2021 to 2023. The table below shows the annual Asset Resilience Ratio data for Prostatype Genomics AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 43.67% | Skr21.49 Million ≈ $2.31 Million |
Skr49.22 Million ≈ $5.30 Million |
+22.09pp |
| 2022-12-31 | 21.58% | Skr6.68 Million ≈ $718.66K |
Skr30.95 Million ≈ $3.33 Million |
-4.54pp |
| 2021-12-31 | 26.12% | Skr10.50 Million ≈ $1.13 Million |
Skr40.20 Million ≈ $4.33 Million |
-- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more